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Introduction: Allogeneic hematopoietic stem cell transplantation 
(HSCT) from a HLA-haploidentical relative is a suitable option 
for patients lacking a compatible donor. We have developed a 
novel method of ex vivo T/B-cell depletion based on the selec-
tive elimination of α/β+ T cells through labeling with a biotinyl-
ated anti-TCR-α/β Ab, followed by incubation with anti-biotin and 
anti-CD19 Ab conjugated to paramagnetic beads (Miltenyi Biotec, 
Germany). Here, we report the results of graft manipulation using 
this methodology.
Methods: Twenty-two children entered the study, 16 with hema-
tological malignancies and 6 with non-malignant disorders. Cell 
therapy products contained up to 60x109 white blood cells (WBC). 
Graft aliquots were used to enumerate residual α/β+ T cells and 
B cells, as well as other immune eff ector cells (type 1 and 2 DC 
precursors, NK cells, invariant NKT cells, classical CD14+CD16- and 
non-classical CD14+CD16+ monocytes).
Results: Median recovery of CD34+ HSC and median number of 
infused CD34+ HSC were 99.3% (range 55.4-100) and 14.7x106/
kg (range 7.9-37), respectively. The graft contained a median 
of 9.9x106 CD3+ T cells/kg (range 3.9-16) and 0.08x106 B cells/
kg (range 0.002-0.32). The log-depletion of α/β+ T cells was 4.1 
(range 3.33-4.96); the median number of transplanted α/β+ T cells 
was 42x103/kg (range 3-100.9). Patients received 28.5x106 CD56+ 
NK cells/kg (range 13.6-192.0) and 9.1x106 γ/δ+ T cells/kg (range 
3.7-106.0). The grafts were also enriched in DC1 and DC2 (0.11% 
of BDCA-1+ cells, range 0.02-0.43; 0.61% of BDCA-3+ cells, range 
0.02-1.17); 0.66% of BDCA-2+ cells, range 0.25-1.28, and 0.28% 
of BDCA-4+ cells, range 0.02-1.16), as well as in non-classical 
CD14+CD16+ monocytes (10.0%, range 4.7-17.5), which may pre-
dict a reduced incidence of GVHD after allogeneic HSCT. All pts 
rapidly engrafted, with the median time to reach 500 neutrophils 
and 50,000 platelets per μl of blood being 12 days (range 10-16) 
and 13 days (range 12-18), respectively. Only 2 pts developed skin 
grade I/II acute GVHD, while no pt had visceral acute GVHD. With 
a median follow-up of 6 months (range 2-8), no pt died of trans-
plant-related complications.  
Conclusions: The results of immunomagnetic removal of α/β+ 
T cells and B cells were robust and reproducible. The grafts were 
enriched in CD34+ HSC, as well as in immune eff ector cells impli-
cated leukemia and GVHD control, such as γ/δ+ T cells, NK cells, 
DC1, DC2 and non-classical monocytes.
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Background: Cord blood banking process is subjected to a wide 
range of procedures variability, despite international standards 
aimed at standardizing the process. Only single bank analyses of 
laboratory variables have been reported so far. Eurocord and Net-
cord have launched a retrospective analysis aimed at assessing 
whether the major variables associated with the banking process 
had an impact on transplantation outcome. 
Methods: With the aim of analyzing the banking procedures, we 
selected an homogenous population of patients who 1: received 
a single CBT with a TNC > 3.0x10e7/kg at freezing, 2: had Acute 
Leukemia in remission, 3: were transplanted in EBMT Centers 
after 1997, 4: had availability of clinical follow-up, and 5: bank 
could be identifi ed. A specifi c questionnaire was circulated to the 
banks, aimed to assess the variables associated to banking of the 
selected cord blood units (CBU), from processing to shipment. In 
particular, CBU volume reduction (VR) technologies (analyzed as 
below or above 30mL after processing) and cells viability assess-
ment in thawed sample were investigated. Questionnaires were 
answered by 38/48 Banks worldwide and 677 patients met the 
eligibility criteria. 
Results: Table 1 reports patient, disease and transplant characteris-
tics. VR was performed in 399 out of 677 patients and its extension 
(≤/>30 mL) did not infl uence any clinical endpoints. Therefore, all 
multivariate analyses were performed including VR (yes/no). Tech-
nologies for viability assessment on a thawed sample were diff er-
ent across the banks (32% Trypan-Blue, 33% Acridine Orange, 34% 
7-ADD) and were not analyzed for outcomes. Neutrophil recovery 
was 87% for patients given either a VR-CBU or an unmanipulated 
CB. NRM at 100 days and at two years were 14% and 29% for 
patients given a VR CBU, and 19% and 31% for those without VR, 
respectively (p=ns). VR was not associated with any outcome dif-
ferences in a multivariate analysis which included CB age, year of 
CB collection, year of Tx, patient age, diagnosis, status at Tx, Nr of 
mismatches, cells dose, CMV status.
Conclusions: In this Registry study, manipulation of the CBUs 
aimed at volume reduction was not shown to infl uence the clini-
cal outcome, indicating a satisfactory validation of the associated 
technologies across the banks. Cells viability assessment meth-
odology varied among banks. Further eff orts to standardize the 
quality controls before CBU release are needed.
